A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors

Trial Profile

A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs ARRY 382 (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 10 May 2017 According to an Array BioPharma media release, the company expects to initiate expansion in melanoma and non-small cell lung cancer shortly.
    • 09 Feb 2017 According to an Array BioPharma media release, the company expects to complete the phase I portion of thsi trial in March 2017 and to initiate phase II expansion in melanoma and non-small cell lung cancer during April 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top